(Reuters) – AbbVie expects its share of Botox in the aesthetics market to remain strong in the fourth quarter, despite recent launches of newer, longer-acting products by rival companies, the company’s executive said on Wednesday.
“We’ve been incredibly efficient at maintaining our leading share position of about 68%,” AbbVie Chief Commercial Officer Jeffrey Stewart said at the J.P.Morgan healthcare conference, adding that the longer-acting products from rivals have “not moved at all”.
(Reporting by Leroy Leo and Pratik Jain in Bengaluru; Editing by Pooja Desai)
Comments